These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 31526843)

  • 1. Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
    Holstein SA; Al-Kadhimi Z; Costa LJ; Hahn T; Hari P; Hillengass J; Jacob A; Munshi NC; Oliva S; Pasquini MC; Shi Q; Stadtmauer EA; Waldvogel SL; McCarthy PL
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):e7-e15. PubMed ID: 31526843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
    Holstein SA; Ye JC; Howard A; Bhutani M; Gormley N; Hahn T; Hillengass J; Krishnan A; Landgren CO; Munshi NC; Oliva S; Owen RG; Pasquini MC; Puig N; Weinhold N; Weisel K; McCarthy PL
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):e89-e97. PubMed ID: 30408566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
    Holstein SA; Howard A; Avigan D; Bhutani M; Cohen AD; Costa LJ; Dhodapkar MV; Gay F; Gormley N; Green DJ; Hillengass J; Korde N; Li Z; Mailankody S; Neri P; Parekh S; Pasquini MC; Puig N; Roodman GD; Samur MK; Shah N; Shah UA; Shi Q; Spencer A; Suman VJ; Usmani SZ; McCarthy PL
    Biol Blood Marrow Transplant; 2020 Oct; 26(10):e247-e255. PubMed ID: 32589921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.
    Holstein SA; Avet-Loiseau H; Hahn T; Ho CM; Lohr JG; Munshi NC; Paiva B; Pasquini MC; Tario JD; Usmani SZ; Wallace PK; Weisel K; McCarthy PL
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):641-648. PubMed ID: 29242112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.
    Holstein SA; Bahlis N; Bergsagel PL; Bhutani M; Bolli N; Brownstein C; Demolis P; Foureau D; Gay F; Ghobrial IM; Gormley N; Hillengass J; Kaiser M; Maus MV; Melenhorst JJ; Merz M; Dwyer MO; Paiva B; Pasquini MC; Shah N; Wong SW; Usmani SZ; McCarthy PL
    Transplant Cell Ther; 2021 Oct; 27(10):807-816. PubMed ID: 34107340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.
    Holstein SA; Asimakopoulos F; Azab AK; Bianchi G; Bhutani M; Crews LA; Cupedo T; Giles H; Gooding S; Hillengass J; John L; Kaiser S; Lee L; Maclachlan K; Pasquini MC; Pichiorri F; Shah N; Shokeen M; Shy BR; Smith EL; Verona R; Usmani SZ; McCarthy PL
    Transplant Cell Ther; 2022 Aug; 28(8):446-454. PubMed ID: 35605882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis.
    Avet-Loiseau H; Ludwig H; Landgren O; Paiva B; Morris C; Yang H; Zhou K; Ro S; Mateos MV
    Clin Lymphoma Myeloma Leuk; 2020 Jan; 20(1):e30-e37. PubMed ID: 31780415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma.
    Glavey SV; Ghobrial IM
    Expert Rev Hematol; 2015 Jun; 8(3):273-5. PubMed ID: 25804827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma.
    Bhutani M; Foureau D; Zhang Q; Robinson M; Wynn AS; Steuerwald NM; Druhan LJ; Guo F; Rigby K; Turner M; Slaughter D; Friend R; Atrash S; Symanowski JT; Avalos BR; Copelan EA; Voorhees PM; Usmani SZ
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):459-465. PubMed ID: 30481597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple Myeloma: The CAR T-cell Therapy Landscape.
    Cancer Discov; 2020 Feb; 10(2):OF6. PubMed ID: 31915196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
    Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
    Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
    Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
    BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal Residual Disease in Multiple Myeloma: Ready for Prime Time?
    Mina R; Bonello F; Oliva S
    Cancer J; 2021 May-Jun 01; 27(3):247-255. PubMed ID: 34549914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use?
    Scott SD; Fletcher M; Whitehouse H; Whitby L; Yuan C; Mazzucchelli S; Lin P; de Tute R; Dorwal P; Wallace PK; Tembhare P; Arroz M; Snowden JA; Chantry AD; Barnett D
    Cytometry B Clin Cytom; 2019 May; 96(3):201-208. PubMed ID: 30565840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.
    Costa LJ; Derman BA; Bal S; Sidana S; Chhabra S; Silbermann R; Ye JC; Cook G; Cornell RF; Holstein SA; Shi Q; Omel J; Callander NS; Chng WJ; Hungria V; Maiolino A; Stadtmauer E; Giralt S; Pasquini M; Jakubowiak AJ; Morgan GJ; Krishnan A; Jackson GH; Mohty M; Mateos MV; Dimopoulos MA; Facon T; Spencer A; Miguel JS; Hari P; Usmani SZ; Manier S; McCarthy P; Kumar S; Gay F; Paiva B
    Leukemia; 2021 Jan; 35(1):18-30. PubMed ID: 32778736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
    Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?
    Kothari S; Hillengass J; McCarthy PL; Holstein SA
    Curr Hematol Malig Rep; 2019 Feb; 14(1):39-46. PubMed ID: 30671912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
    Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J
    Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596
    [No Abstract]   [Full Text] [Related]  

  • 19. Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.
    Rihova L; Vsianska P; Bezdekova R; Kralova R; Penka M; Krejci M; Pour L; Hájek R
    Klin Onkol; 2017; 30(Supplementum2):21-28. PubMed ID: 28903567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017.
    Terpos E;
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):321-334. PubMed ID: 29576386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.